Mr. Speaker, we have responded. Health research on the new techniques, such as this one, is critically important.
That is why we have invested $120 million for neurological disease, including $5.3 million for MS. In addition, we invested $16 million in budget 2010 to CIHR for research. I have also asked Dr. Alain Beaudet, president of CIHR, to provide me with advice on how to advance this important research.
I continue to work with the MS Society and CIHR. We are encouraging MS researchers to put applications forward for this new treatment.